#China #Suzhou #Daiichi Sankyo #Innovent Biologics #Vanflyta

Innovent Biologics and Daiichi Sankyo Enter Exclusive Partnership for Vanflyta® Commercialization in China

In a significant move to improve treatment options for cancer patients in China, Innovent Biologics, Inc. has announced an exclusive agreement with Daiichi Sankyo for the commercialization of Vanflyta® (quizartinib). This partnership, unveiled on August 9, 2026, aims to enhance access to this innovative medication for patients suffering from newly diagnosed FLT3-ITD positive acute myeloid leukemia (AML).

A Step Forward in Hematology

Innovent Biologics, known for its dedication to addressing the needs of patients, has been expanding its portfolio in the field of hematology. The agreement with Daiichi Sankyo will see Innovent holding exclusive commercialization rights for Vanflyta®, while Daiichi Sankyo will handle the development, manufacturing, and supply chain processes. This collaboration represents a potentially transformative step for patients dealing with this aggressive form of leukemia, with Vanflyta® now positioned as a cornerstone treatment option.

Recent Approval and Treatment Protocol

Vanflyta® received approval in China in June 2026, marking an important milestone. The medication is indicated for use alongside standard cytarabine and anthracycline induction and subsequent cytarabine consolidation. Furthermore, it is prescribed as a maintenance monotherapy following consolidation chemotherapy for adult patients diagnosed with FLT3-ITD positive AML, as identified through validated diagnostic testing, notably derived from results of the pivotal QuANTUM-First trial.

Vivian Zhang, Innovent's Executive Director and Chief Commercial Officer, articulated the excitement surrounding this partnership by stating, "This collaboration with Daiichi Sankyo is a significant milestone for our hematology franchise. Adding Vanflyta® to our product lineup will further solidify our commitment to providing innovative therapies for patients in need."

The Importance of Collaboration

The emphasis on working together to bring innovative medicines to the market is echoed by Michio Hayashi, President of Daiichi Sankyo in China. He noted that by leveraging their research capabilities alongside Innovent's commercial strengths, the partnership is set to enhance patient access to Vanflyta® significantly. This will not only potentially improve outcomes for patients diagnosed with FLT3-ITD positive AML but also contribute to broader healthcare goals in the region.

AML Landscape in China

The global rise in leukemia cases is alarming; in 2022 alone, over 487,000 cases of leukemia were reported, resulting in more than 305,000 deaths. Among these cases, AML constitutes a significant portion and is particularly prevalent in adults. Statistics from China indicate that nearly 82,000 individuals were diagnosed with leukemia last year, underscoring the urgent need for effective treatment options. Given that AML accounts for roughly 50% of leukemia cases in the country, the introduction of Vanflyta® comes at a crucial time.

Understanding FLT3-ITD Positive AML

Approximately 25% of AML cases involve FLT3-ITD mutations, which present a serious challenge due to their aggressive nature and high relapse rates. Vanflyta® has been developed as a type II FLT3 inhibitor specifically targeting these mutations, offering a new hope for patients facing such diagnoses. With a substantial focus on oncology, Daiichi Sankyo aims to be at the forefront of innovative treatment options that can change the lives of those battling cancer.

Innovent's Vision

Founded in 2011, Innovent Biologics is committed to providing high-quality biopharmaceuticals and has maintained a robust growth trajectory. Their portfolio encompasses not only hematology treatments but also therapies for cardiovascular, metabolic, and autoimmune diseases, showcasing their broad expertise in the biopharmaceutical sector. This agreement with Daiichi Sankyo adds yet another product to Innovent's growing commercialization efforts, expanding their reach and reinforcing their market presence.

In summary, the collaboration between Innovent Biologics and Daiichi Sankyo represents a pivotal advancement in the treatment of AML in China. By combining resources and expertise, they aim to provide timely and innovative solutions for patients, ultimately enhancing the quality of care available in the healthcare landscape.